Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Feasibility study of alternate-day S-1 as adjuvant chemotherapy for gastric cancer: a randomized controlled trial.

Tatebe S, Tsujitani S, Nakamura S, Shimizu T, Yamane N, Nishidoi H, Kurisu Y, Kanayama H, Ogawa H, Ikeguchi M.

Gastric Cancer. 2014;17(3):508-13. doi: 10.1007/s10120-013-0289-z. Epub 2013 Aug 15.

PMID:
23948997
2.

Randomized phase II study of S-1 dosing schedule for resected colorectal cancer.

Matsuda C, Uemura M, Nakata K, Shingai T, Nishimura J, Hata T, Ikenaga M, Takemasa I, Mizushima T, Kato T, Ikeda M, Ohue M, Murata K, Hasegawa J, Satoh T, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M.

BMC Cancer. 2015 Jun 3;15:452. doi: 10.1186/s12885-015-1476-6.

3.

[Alternate-day oral therapy with S-1 for adjuvant chemotherapy of gastric cancer].

Takebayashi K, Kawai Y, Tagi T, Matsumura M, Shimizu K, Yamamoto H, Mekata E, Tani T, Sato M.

Gan To Kagaku Ryoho. 2012 Mar;39(3):385-7. Japanese.

PMID:
22421764
4.

Optimal schedule of adjuvant chemotherapy with S-1 for stage III colon cancer: study protocol for a randomized controlled trial.

Yoshimura K, Uehara K, Tojima Y, Kawai S, Mokuno Y, Maeda A, Kyokane T, Kobayashi S, Yoshioka Y, Nagino M.

Trials. 2013 Jan 15;14:17. doi: 10.1186/1745-6215-14-17.

5.

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M.

Lancet Oncol. 2008 Mar;9(3):215-21. doi: 10.1016/S1470-2045(08)70035-4. Epub 2008 Feb 20.

PMID:
18282805
6.

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.

Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group.

N Engl J Med. 2007 Nov 1;357(18):1810-20. Erratum in: N Engl J Med. 2008 May 1;358(18):1977.

7.

A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703).

Kodera Y, Ishiyama A, Yoshikawa T, Kinoshita T, Ito S, Yokoyama H, Mochizuki Y, Ito H, Tsuburaya A, Sakamoto J, Nakao A; Chubu Clinical Cancer Group.

Gastric Cancer. 2010 Aug;13(3):197-203. doi: 10.1007/s10120-010-0559-y. Epub 2010 Sep 5.

PMID:
20820990
8.

A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.

Tsuchiya T, Nagayasu T, Yamasaki N, Matsumoto K, Miyazaki T, Tagawa T, Nakamura A, Minami H, Taniguchi H, Akamine S, Hisano H, Taniguchi Y.

Clin Lung Cancer. 2012 Nov;13(6):464-9. doi: 10.1016/j.cllc.2012.01.005. Epub 2012 Mar 14.

PMID:
22424872
9.

Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil and oteracil potassium) for colorectal cancer.

Kawahara H, Watanabe K, Ushigome T, Noaki R, Kobayashi S, Yanaga K.

Hepatogastroenterology. 2012 Jan-Feb;59(113):134-7. doi: 10.5754/hge09684.

PMID:
22251528
10.

Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer.

Yamaue H, Shimizu A, Hagiwara Y, Sho M, Yanagimoto H, Nakamori S, Ueno H, Ishii H, Kitano M, Sugimori K, Maguchi H, Ohkawa S, Imaoka H, Hashimoto D, Ueda K, Nebiki H, Nagakawa T, Isayama H, Yokota I, Ohashi Y, Shirasaka T.

Cancer Chemother Pharmacol. 2017 Apr;79(4):813-823. doi: 10.1007/s00280-017-3250-8. Epub 2017 Mar 1.

PMID:
28251282
11.

Feasibility study of S-1 for resectable gastric cancer with peritoneal seeding.

Fujitani K, Tsujinaka T, Hirao M.

Hepatogastroenterology. 2003 May-Jun;50(51):889-92.

PMID:
12828112
12.

Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer.

Kim SJ, Kim YJ, Kim JH, Park DJ, Kim HH, Lee JS, Lee KW.

Cancer Sci. 2013 Jan;104(1):116-23. doi: 10.1111/cas.12044. Epub 2012 Nov 28.

13.

Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity.

Sakuma K, Hosoya Y, Arai W, Haruta H, Ui T, Kurashina K, Saito S, Hirashima Y, Yokoyama T, Zuiki T, Hyodo M, Nagai H, Yasuda Y, Shirasaka T.

Int J Clin Oncol. 2010 Apr;15(2):166-71. doi: 10.1007/s10147-010-0036-y. Epub 2010 Mar 2.

PMID:
20195683
14.

Feasibility study of S-1 adjuvant chemotherapy in patients with colorectal cancer.

Ogawa M, Watanabe M, Kobayashi T, Eto K, Oda A, Anan T, Hayashi T, Mitsuyama Y, Yanaga K.

Int J Clin Oncol. 2013 Aug;18(4):678-83. doi: 10.1007/s10147-012-0424-6. Epub 2012 May 15.

PMID:
22585427
15.

Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.

Kinoshita T, Nashimoto A, Yamamura Y, Okamura T, Sasako M, Sakamoto J, Kojima H, Hiratsuka M, Arai K, Sairenji M, Fukushima N, Kimura H, Nakajima T.

Gastric Cancer. 2004;7(2):104-9.

PMID:
15224197
16.

Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.

Tsuburaya A, Yoshida K, Kobayashi M, Yoshino S, Takahashi M, Takiguchi N, Tanabe K, Takahashi N, Imamura H, Tatsumoto N, Hara A, Nishikawa K, Fukushima R, Nozaki I, Kojima H, Miyashita Y, Oba K, Buyse M, Morita S, Sakamoto J.

Lancet Oncol. 2014 Jul;15(8):886-93. doi: 10.1016/S1470-2045(14)70025-7. Epub 2014 Jun 18.

PMID:
24954805
17.

A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC).

Ueda Y, Fujimura T, Kinami S, Hirono Y, Yamaguchi A, Naitoh H, Tani T, Kaji M, Yamagishi H, Miwa K; Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC).

Jpn J Clin Oncol. 2006 Aug;36(8):519-22. Epub 2006 Jun 27.

PMID:
16803844
18.

Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).

Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, Esaki T, Furukawa H, Hamada C, Sakata Y.

Gastric Cancer. 2011 Mar;14(1):72-80. doi: 10.1007/s10120-011-0009-5. Epub 2011 Feb 23.

19.

Safety and feasibility of S-1 adjuvant chemotherapy for gastric cancer in elderly patients.

Aoyama T, Yoshikawa T, Watanabe T, Hayashi T, Ogata T, Cho H, Tsuburaya A.

Gastric Cancer. 2012 Jan;15(1):76-82. doi: 10.1007/s10120-011-0068-7. Epub 2011 Jun 30.

PMID:
21717091
20.

Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery.

Okuyama T, Korenaga D, Edagawa A, Itoh S, Oki E, Kawanaka H, Ikeda Y, Kakeji Y, Tateishi M, Tsujitani S, Takenaka K, Maehara Y.

Surg Today. 2012 Aug;42(8):734-40. doi: 10.1007/s00595-012-0129-5. Epub 2012 Jan 27.

PMID:
22278622

Supplemental Content

Support Center